Form 4: Immunovant Chief Development Officer Sells Shares to Cover Tax Obligations

Julia G. Butchko, Chief Development Officer of Immunovant, Inc., sold shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Summary

• On August 21, 2024, Julia G. Butchko, Chief Development Officer of Immunovant, Inc., sold 2,907 shares of common stock at a weighted average price of $31.84 and 120 shares at a weighted average price of $32.32.
• These sales were to cover tax withholding obligations related to the vesting of 7,051 restricted stock units (RSUs) on August 17, 2024, which were part of a grant of 112,816 RSUs on August 17, 2022.
• The sales were mandated by Immunovant's policy requiring tax obligations to be funded by a 'sell to cover' transaction and do not represent a discretionary transaction by Butchko.
• Following the reported transactions, Butchko beneficially owns 440,959 shares of Immunovant common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction related to executive compensation and tax obligations, with no indication of positive or negative sentiment.

Industry Context

Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company officers and directors. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Key Dates